Introduction {#S1}
============

The temporomandibular joint (TMJ) is distinguished from other joints because it is involved in growth of the jaw as well as mastication. Structural features of TMJ are well studied in the clinical field of oral surgery.^[@R1]--[@R3]^ The mandibular condyle is a member of TMJ and composed of cartilage and fibrous layers covering the surface of the joint.^[@R4]^ The condylar cartilage also works as a growth cartilage in mandible, and development and growth of this cartilage is important in the clinical field of orthodontics.^[@R4]^ Embryologically, the mandibular condylar cartilage is the principal secondary cartilage and differs somewhat from primary cartilage skeleton.^[@R5]--[@R7]^ The condylar cartilage derives from alkaline phosphatase (ALP)-positive, *type I collagen* mRNA-expressing progenitor cells continuous with the ossifying mandible^[@R8]--[@R12]^ and progenitor cells of this cartilage (skeletoblasts)^[@R13]^ rapidly differentiate into hypertrophic chondrocytes.^[@R8],[@R10]--[@R13]^ The TMJ, comprising the condylar cartilage, articular disc, and upper and lower joint cavities, is morphologically identified by embryonic day (E) 18.5.^[@R14]^

We previously described several transcription factors involved in bone and cartilage formation, including *Runx2, Osterix*, and *Sox9*, which regulate the formation of the condylar cartilage.^[@R15],[@R16]^ In addition, several growth factors and their receptors, such as transforming growth factors,^[@R17],[@R18]^ bone morphogenetic proteins,^[@R12]^ fibroblast growth factors,^[@R19],[@R20]^ and insulin-like growth factors (IGFs)^[@R20]--[@R29]^ are also involved in the formation/growth of the mandibular condylar cartilage. IGFs are polypeptide growth factors that control pre- and postnatal development and growth in various tissues via the endocrine, paracrine, and autocrine systems. The IGF ligands IGF-I and IGF-II are involved in cell differentiation, proliferation, morphogenesis, growth, and control of metabolic functions. IGF-I is a somatomedin, a growth hormone mediator that stimulates the synthesis of IGF-I by negative feedback mechanisms. IGF-I is synthesized mainly in the liver, but it is also produced locally in various tissues.^[@R30]--[@R32]^ Although there is a 76% homology between the IGF-I and IGF-II peptides, IGF-II is thought to have an important role mainly during the fetal period. Furthermore, IGFs bind to specific receptors, but the tyrosine kinase receptor IGF-I-receptor (IGF-IR) mediates most of the actions of IGF.^[@R30]--[@R32]^ Studies using immunohistologic and molecular biologic techniques confirmed that IGF-I and IGF-II are expressed in the upper layer of the condylar cartilage in young rat^[@R21],[@R22]^ and in aged mice.^[@R23]^ The *IGF-I* gene is highly expressed in the perichondrium fraction of the condylar cartilage in neonatal mice.^[@R24]^ In organ cultures of the mandibular condyle, exogenous IGF-I significantly increases the uptake of ^3^H-thymidine and ^35^S-sulfate by the condylar cartilage.^[@R25],[@R26]^ *In vivo* experiments revealed that local administration of IGF-I into the articular cavity of the TMJ accelerates endochondral bone growth of the mandibular condyle,^[@R27]^ and IGF-I is also involved in chondrocyte apoptosis in the condylar cartilage.^[@R28]^ In the condylar cartilage of young rats fitted with a mandibular propulsive appliance, *IGF-I* mRNA expression is increased,^[@R21]^ indicating that IGF-I mediates the effects of mechanical stimulation to promote local growth of the mandibular condyle. Furthermore, IGF-IR immunostaining is also observed in the upper layer of condylar cartilage in young rat^[@R20],[@R29]^ and in aged mice.^[@R23]^ The *IGF-IR* gene is highly expressed in the cartilage fraction in neonatal mice.^[@R24]^ Together, these findings indicate that both exogenous and endogenous IGFs affect the growth and development of the condylar cartilage during the postnatal period. The involvement of IGFs and the IGF-IR in the initial formation of the condylar cartilage, however, has not been investigated. Meanwhile, IGF-I and IGF-II in the serum and other extracellular environments are bound to IGF binding proteins (IGFBPs), which modulate the endocrine actions of IGFs by inhibiting or potentiating the bioavailability of IGFs for binding their receptors. Additionally, some IGFBPs have IGF-independent actions.^[@R33]^ In the cartilage tissue, although IGFBP expression is well studied in the growth plates of long bones,^[@R34]^ only a few studies have been performed in the mandibular condylar cartilage of aged mice,^[@R23]^ or in young rats,^[@R35]^ and none have been performed in fetuses. These results made us hypothesize that the IGF system including IGFs, IGF-IR, and IGFBPs is also involved in the initial formation of the condylar cartilage. Since we have established the experimental system analyzing initial formation process of mouse condylar cartilage,^[@R8],[@R10],[@R11],[@R15]^ we performed the present *in situ* hybridization study using this system.

Materials and Methods {#S2}
=====================

All animals were housed in facilities approved by the Health Sciences University of Hokkaido. Our animal-use protocol conformed to the Institutional Administrator\'s Manual for Laboratory Animal Care and Use (NIH publication no. 88--2959) and was reviewed and approved by the Screening Committee for Animal Research of the Health Sciences University of Hokkaido.

Tissue preparation
------------------

A total of 10 pregnant ICR mice, at E13.0--18.5 (08:00 am on the day of the vaginal plug was designated as E0), were used for this study. At each time point, the pregnant mice were killed by cervical dislocation under ether anesthesia, after which each fetal mouse was killed by cervical dislocation. The heads were then removed and immersed in 4% paraformaldehyde (0.1 M phosphate buffer, pH 7.4) for 1 d at 4°C. The specimens were embedded in paraffin using standard procedures. Sections (5 µm) were cut in the coronal plane, perpendicular to the sagittal plane, and parallel to the long axis of the condylar or angular process of the mandible. Sections were stained with 0.1% toluidine blue (0.1 M phosphate buffer, pH 7.4) for histologic observations.

*In situ* hybridization
-----------------------

RNA probes for *IGF-I, IGF-II*, and *IGF-IR*, and *IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-5*, and *IGFBP-6*, were used in previous studies.^[@R36],[@R37]^ *IGBP-1* mRNA is expressed only in the liver,^[@R36]^ therefore it was excluded in the present study. Probes were labeled with \[^35^S\]-UTP, as previously described.^[@R15],[@R16]^ Sections were dipped in emulsion (NTB, Kodak, Rochester, NY, USA) after hybridization and RNAase treatment, and then exposed for 1 wk at 4°C for autoradiography. Sense probes were used as negative controls. Although we did not accept some quantitative analyzes, we examined three different samples for each embryonic day to confirm the consistency of results obtained.

Results {#S3}
=======

*In situ* hybridization for *IGF-I*, *IGF-II* and *IGF-IR* mRNA in developing condylar cartilage
------------------------------------------------------------------------------------------------

At E13.0, mandibular bone (MB) was clearly formed lateral to the Meckel\'s cartilage (MC), and the developing masseter muscle (MM) was recognized lateral to the mandibular bone ([Figure 1](#F1){ref-type="fig"}a). *IGF-I* mRNA was expressed in the mesenchymal tissue around mandibular bone ([Figure 1](#F1){ref-type="fig"}b, arrows), in the MM ([Figure 1](#F1){ref-type="fig"}b), and in the perichondrium of Meckel\'s cartilage ([Figure 1](#F1){ref-type="fig"}b, arrowheads), but not in the mandibular bone and Meckel\'s cartilage. *IGF-II* mRNA showed a similar expression pattern to that of *IGF-I* ([Figure 1](#F1){ref-type="fig"}c). *IGF-IR* mRNA was strongly expressed in the masseter muscle (MM), but not in the other areas at this stage ([Figure 1](#F1){ref-type="fig"}d). At E14.0, the anlage of the future condylar process (termed the condylar anlage), consisting of a mesenchymal cell condensation, was clearly identifiable in the posterior position of the ossifying mandible ([Figure 1](#F1){ref-type="fig"}e, arrow), as previously descri bed.^[@R8],[@R10],[@R11],[@R15]^ Matrix metachromasia, indicative of cartilage formation, was not observed in the anlage at this stage ([Figure 1](#F1){ref-type="fig"}e). *IGF-I* mRNA was expressed in the MM ([Figure 1](#F1){ref-type="fig"}f), in the periosteum of mandibular bone ([Figure 1](#F1){ref-type="fig"}f, arrowhead), and in the outer region of the condylar anlage continuous with the periosteum ([Figure 1](#F1){ref-type="fig"}f, arrow). The expression pattern of *IGF-II* mRNA was similar to that of *IGF-I,* but the *IGF-II* mRNA-positive area was broader ([Figure 1](#F1){ref-type="fig"}g). *IGF-IR* mRNA was expressed in the MM ([Figure 1](#F1){ref-type="fig"}h) and in the center of the condylar anlage ([Figure 1](#F1){ref-type="fig"}h, arrow). At E15.0, a metachromatically-stained matrix was first detected in the condylar anlage, indicating the initial formation of the condylar cartilage ([Figure 1](#F1){ref-type="fig"}i, arrow). The region posterior to the newly formed cartilage, consisting of a mesenchymal cell condensation, was named *the embryonic zone* (E) ([Figure 1](#F1){ref-type="fig"}i), as previously described.^[@R10],[@R15]^ The outer layer continuous with the periosteum was identified as the perichondrium of newly formed condylar cartilage (PC) ([Figure 1](#F1){ref-type="fig"}i). *IGF-I* and *IGF-II* mRNA were expressed in the perichondrium ([Figure 1](#F1){ref-type="fig"}j,k, arrows), but the *IGF-II* positive area was broader. *IGF-IR* mRNA was expressed in the embryonic zone and in the upper part of the newly formed cartilage ([Figure 1](#F1){ref-type="fig"}l, arrow), but not in the lower part ([Figure 1](#F1){ref-type="fig"}l, arrowhead).

Figure 1Mandible cut in coronal plane at embryonic day (E) 13.0 (a--d), 14.0 (e--h), and 15.0 (i--l). Toluidine blue staining (a, e, i), and *in situ* hybridization for *IGF-I* (b, f, j), -II (c, g, k), and *IGF-IR* (d, h, l) mRNA. a--d, *IGF-I* and *-II* mRNA were expressed in mesenchymal tissue (arrows) around mandibular bone (MB), and *IGF-IR* mRNA was expressed in the masseter muscle (MM). e--h, *IGF-I* and -*II* mRNA were expressed in the periosteum of mandibular bone (f-g, arrowheads), and in the outer region of the condylar anlage (f-g, arrows); *IGF-II* mRNA-positive area was broader; *IGF-IR* mRNA was expressed in the center of the condylar anlage (h, arrow). i--l, *IGF-I* and -*II* mRNA were expressed in the perichondrium (j--k, arrows), and *IGF-IR* mRNA was expressed in the embryonic zone and in the upper part of the newly formed cartilage (l, arrow). MC, Meckel\'s cartilage. Scale bar: 100 µm.

At E16.0, the zones usually present in the growing condyle^[@R38]^ had become distinct: the fibrous cell (articulation) zone, polymorphic cell zone, flattened cell zone, and hypertrophic cell zone. The condylar cartilage had increased in length, especially the hypertrophic cell zone ([Figure 2](#F2){ref-type="fig"}a). *IGF-I* mRNA was expressed in the perichondrium and in the fibrous cell zone continuous with the perichondrium ([Figure 2](#F2){ref-type="fig"}b, arrows). *IGF-II* mRNA was expressed in the perichondrium, and in the fibrous cell zone ([Figure 2](#F2){ref-type="fig"}c, arrows) as well as in the polymorphic cell zone ([Figure 2](#F2){ref-type="fig"}c, arrowhead). *IGF-IR* mRNA was expressed in the zones from the fibrous to flattened cell zone ([Figure 2](#F2){ref-type="fig"}d, arrow), but not in the hypertrophic cell zone ([Figure 2](#F2){ref-type="fig"}d, arrowhead).

Figure 2Condylar cartilage in coronal plane at embryonic day (E) 16.0. Toluidine blue staining (a), and *in situ* hybridization for *IGF-I* (b), -*II* (c), and *IGF-IR* (d) mRNA. The fibrous cell zone (F), polymorphic cell zone (P), flattened cell zone (Fl), and hypertrophic cell zone (H) were established. *IGF-I* and -*II* mRNA were expressed in the perichondrium and in the fibrous cell zone (b--c, arrows), and *IGF-II* mRNA was further expressed in the polymorphic cell zone (c, arrowhead). *IGF-IR* mRNA was expressed in zones from the fibrous to flattened cell zone (d, arrow). Scale bar: 100 µm.

Negative controls using sense probes showed no positive reactions at any stage examined (*data not shown*). We examined three different samples for each embryonic day and the same results were obtained each time.

*In situ* hybridization for *IGFBPs* mRNA in developing condylar cartilage and temporomandibular joint
------------------------------------------------------------------------------------------------------

Among *IGFBPs, IGFBP-6* mRNA was not significantly expressed in condylar cartilage/TMJ throughout the experimental period, and *IGFBP-3* mRNA was mainly expressed in invading capillaries, as previously described in fetal long bone.^[@R36]^ Thus, we showed the expression of these molecules at E16.0 as representative ([Figure 3](#F3){ref-type="fig"}m,n) and mainly described the expression of *IGFBP-2*, *IGFBP-4*, and *IGFBP-5* mRNA in the present study.

Figure 3Mandible cut in coronal plane at embryonic day (E) 14.0 (panels a--d), 15.0 (panels e--h), and 16.0 (panels i--n). Toluidine blue staining (a, e, i), and *in situ* hybridization for *IGFBP-2* (b, f, j), *-4* (c, g, k), *-5* (d, h, l), *-3* (m), and *-6* (n) mRNA. a--d, *IGFBP-2* and *-4* mRNA was only slightly expressed in the mesenchyme around condylar anlage (b-c, arrows); *IGFBP-5* mRNA was expressed in the periosteum of the mandibular bone and in the outer region of the condylar anlage (d, arrows). e--h, *IGFBP-2* mRNA was only slightly expressed in the anlage of the future articular disc (f, arrow); *IGFBP-4* mRNA was strongly expressed in this anlage (g, arrow). *IGFBP-5* mRNA was expressed in the outer layer of the perichondrium (h, arrows). i--n, Enhanced *IGFBP-2* mRNA was recognized in the anlagen of the articular disc and lower joint cavity (j, arrow); *IGFBP-4* mRNA was strongly expressed in the anlagen of the articular disc and lower joint cavity (k, arrow), as well as in the continuous mesenchymal tissue including the outer layer of the perichondrium (k, arrowhead); *IGFBP-5* mRNA was expressed in the outer layer of the perichondrium/fibrous cell zone (l, arrow), *IGFBP-3* mRNA was mainly expressed in the invading capillaries (m, arrowheads), and *IGFBP-6* mRNA was not significantly expressed (n). MB, mandibular bone; MC, Meckel\'s cartilage; E, embryonic zone; PC, perichondrium; MF, mandibular fossa. Scale bar: 100 µm.

At E14.0, the condylar anlage was recognized posterior to the ossifying mandible, as described above ([Figure 3](#F3){ref-type="fig"}a, arrow). *IGFBP-2* and *IGFBP-4* mRNA was only slightly expressed in the mesenchyme around the condylar anlage ([Figure 3](#F3){ref-type="fig"}b,c, arrows). *IGFBP-5* mRNA was clearly expressed in the periosteum of the mandibular bone, and in the outer region of the condylar anlage continuous with the periosteum ([Figure 3](#F3){ref-type="fig"}d, arrows).

At E15.0, adding to the newly formed condylar cartilage with the perichondrium and the embryonic zone ([Figure 3](#F3){ref-type="fig"}e, arrow), another mesenchymal condensation, corresponding to an anlage of the future articular disc, was observed outside the condylar cartilage ([Figure 3](#F3){ref-type="fig"}e, arrowhead), as previously described.^[@R14]^ *IGFBP-2* mRNA was only slightly expressed in this mesenchymal condensation ([Figure 3](#F3){ref-type="fig"}f, arrow), but *IGFBP-4* mRNA was strongly expressed within this condensation ([Figure 3](#F3){ref-type="fig"}g, arrow). *IGFBP-5* mRNA was expressed in the outer layer of the perichondrium ([Figure 3](#F3){ref-type="fig"}h, arrow).

At E16.0, an anlage of the future articular disc ([Figure 3](#F3){ref-type="fig"}i, arrow) and lower joint cavity ([Figure 3](#F3){ref-type="fig"}i, arrowhead) were clearly discriminated as a dense mesenchymal condensation and loose mesenchymal tissue, respectively. The ossifying mandibular fossa (MF) in the temporal bone was clearly identified ([Figure 3](#F3){ref-type="fig"}i). Enhanced *IGFBP-2* mRNA was recognized in the anlagen of the articular disc and lower joint cavity ([Figure 3](#F3){ref-type="fig"}j, arrow). *IGFBP-4* mRNA was strongly expressed in the anlagen of the articular disc and lower joint cavity ([Figure 3](#F3){ref-type="fig"}k, arrow), as well as in the continuous mesenchymal tissue, including the outer layer of the perichondrium ([Figure 3](#F3){ref-type="fig"}k, arrowhead). *IGFBP-5* mRNA was expressed in the outer layer of the perichondrium/fibrous cell zone ([Figure 3](#F3){ref-type="fig"}l, arrow) as well as in the periosteum of the mandibular fossa ([Figure 3](#F3){ref-type="fig"}l, arrowhead). Compared to *IGFBP-4*, *IGFBP-5* mRNA expression was restricted to the narrow layer. Furthermore, *IGFBP-3* mRNA was mainly expressed in invading capillaries ([Figure 3](#F3){ref-type="fig"}m, arrowheads), and *IGFBP-6* mRNA was not significantly expressed ([Figure 3](#F3){ref-type="fig"}n). The expression patterns of these two molecules were similar in all samples examined (*data not shown*).

At E18.5, endochondral ossification had begun in the condylar cartilage ([Figure 4](#F4){ref-type="fig"}a). At higher magnification, the upper joint cavity (UJC) ([Figure 4](#F4){ref-type="fig"}b) was clearly formed and fibrous mesenchymal tissue ([Figure 4](#F4){ref-type="fig"}b, arrow) was observed superior to the upper joint cavity. At the same time, the lower joint cavity (LJC) ([Figure 4](#F4){ref-type="fig"}b) remained as mesenchymal tissue at this stage. *IGFBP-2* mRNA was not expressed in the perichondrium ([Figure 4](#F4){ref-type="fig"}c, arrow), but clearly expressed in the fibrous mesenchymal tissue facing the upper joint cavity ([Figure 4](#F4){ref-type="fig"}d, arrow) and in the anlagen of the articular disc and lower joint cavity ([Figure 4](#F4){ref-type="fig"}d, arrowheads). *IGFBP-4* mRNA was continuously expressed in the perichondrium ([Figure 4](#F4){ref-type="fig"}e, arrow), in the anlagen of the articular disc and lower joint cavity ([Figure 4](#F4){ref-type="fig"}f, arrowhead), as well as in the continuous mesenchymal tissue, including the outer layer of the perichondrium ([Figure 4](#F4){ref-type="fig"}f, asterisk), but reduced in the fibrous mesenchymal tissue facing the upper joint cavity ([Figure 4](#F4){ref-type="fig"}f, arrow). *IGFBP-5* mRNA was expressed in the outer layer of the perichondrium/fibrous cell zone ([Figure 4](#F4){ref-type="fig"}h, arrow) and in the periosteum of the mandibular fossa ([Figure 4](#F4){ref-type="fig"}-h, arrowhead).

Figure 4Condylar cartilage (a--h) and angular cartilage (i--l) in coronal plane at embryonic day (E) 18.5. b, d, f, h, enlargements of rectangular areas in a, c, e, g, respectively. Toluidine blue staining (a, b, i), and *in situ* hybridization for *IGFBP-2* (c, d, j), -*4* (e, f, k), *-5* (g, h, l). a--h, *IGFBP-2* mRNA was expressed in the fibrous mesenchymal tissue facing the upper joint cavity (d, arrow), and in the anlagen of the articular disc and lower joint cavity (d, arrowhead); *IGFBP-4* mRNA was expressed in the perichondrium (e, arrow), in the anlagen of the articular disc and lower joint cavity (f, arrowhead), as well as in the continuous mesenchymal tissue (f, asterisk), but reduced in the fibrous mesenchymal tissue facing the upper joint cavity (f, arrow); *IGFBP-5* mRNA was expressed in the outer layer of the perichondrium/fibrous cell zone (h, arrow). i--l, *IGFBP-2* mRNA was not significantly expressed (j); *IGFBP-4* mRNA was expressed in the perichondrium/fibrous cell zone (k, arrows), and *IGFBP-5* mRNA was expressed in the outer layer of the perichondrium/fibrous cell zone (l, arrows). UJC, upper joint cavity; AD, articular disc; LJC, lower joint cavity; MF, mandibular fossa; AC, angular cartilage; MM, masseter muscle; MPM, medial pterygoid muscle. Scale bar: 100 µm.

The mandibular angular cartilage (AC) at E18.5 formed with zones similar to those of the condylar cartilage, and the masseter muscle (MM) and medial pterygoid muscle (MPM) were attached to it ([Figure 4](#F4){ref-type="fig"}i). The joint structure had not formed, but code-like tissue (presumably future stylomandibular ligament) was attached to the posterior end of the angular cartilage (in [Figure 4](#F4){ref-type="fig"}i, asterisk). *IGFBP-2* mRNA was not significantly expressed in the angular cartilage ([Figure 4](#F4){ref-type="fig"}j). *IGFBP-4* mRNA was expressed in the perichondrium/fibrous cell zone ([Figure 4](#F4){ref-type="fig"}k, arrows) as well as in the code-like tissue ([Figure 4](#F4){ref-type="fig"}k, asterisk). *IGFBP-5* mRNA was expressed in the outer layer of the perichondrium/fibrous cell zone ([Figure 4](#F4){ref-type="fig"}l, arrows) and in the code-like tissue ([Figure 4](#F4){ref-type="fig"}l, asterisk). Negative controls using sense probes showed no positive reactions at any stage examined (*data not shown*). We examined three different samples for each embryonic day and the same results were obtained each time.

Discussion {#S4}
==========

Expression of *IGF-I*, *IGF-II*, and *IGF-IR* mRNA in developing mandibular condylar cartilage
----------------------------------------------------------------------------------------------

In the present study, we first demonstrated the expression of *IGF-I* and *IGF-II* and *IGF-IR* mRNA in developing fetal mouse mandibular condylar cartilage. *IGF-I* and *IGF-II* mRNA expression was diffusely detected in the mes-enchyme around the mandibular bone at E13.0, but *IGF-IR* mRNA was not detected within the mandibular bone. The condylar anlage was morphologically identified at E14.0, and formation of the condylar cartilage was first detected within the condylar anlage at E15.0, as previously reported.^[@R8],[@R10]--[@R12],[@R15]^ During these periods, *IGF-I* and *IGF-II* mRNA expression was restricted to the periosteum and to the outer layer of the condylar anlage/perichondrium/fibrous cell zone, but the *IGF-II* mRNA-positive areas were broader, indicating that *IGF* was expressed around the whole condylar process. *IGF-IR* mRNA was first detected within the condylar anlage at E14.0, suggesting that the presence of *IGF-IR* under an IGF-rich environment triggers subsequent condylar cartilage formation. Further, *IGF-IR* was continuously expressed in the upper part of the condylar cartilage, including the embryonic zone at E15.0 and the polymorphic cell zone at E16.0. These *IGF-IR* mRNA-positive areas have high cell proliferation activity and seem to function as the condylar cartilage growth center.^[@R11],[@R38],[@R39]^ Therefore, *IGF-IR* expression under an IGF-rich environment is also involved in the subsequent growth of the fetal condylar cartilage.

Previous *in vivo* studies demonstrated the expression of *IGF-I* and *IGF-II* mRNA or their immunostaining in the upper layer of the condylar cartilage in young rat^[@R20]--[@R22]^ and in aged mice.^[@R23]^ *IGF-IR* immunostaining is detected in the fibrous cell zone and upper part of the cartilage.^[@R20],[@R23],[@R29]^ These studies and previous *in vitro* experiments^[@R20],[@R25],[@R26]^ indicate that the IGF system affects growth, development, and aging, as well as the reaction to the effects of orthopedic appliances on the condylar cartilage^[@R21]^ during the postnatal period. In addition to these functions, the present results indicate that the IGF system is involved in the initial formation of the condylar cartilage. Our model of *IGFs* and *IGF-IR* expression during mandibular condylar cartilage formation is summarized in [Figure 5](#F5){ref-type="fig"}a. In murine long bone cartilage, representative primary cartilage, IGF expression in initial chondrogenesis is well investigated by Wang *et al.*^[@R34]^ They reported *IGF-I* mRNA expression in surrounding mesenchymal tissue, but not in mesenchymal condensations or newly formed chondrocytes (chondroblasts), whereas strong *IGF-II* mRNA expression was observed in both mesenchymal condensations and chondroblasts. Additionally, *IGF-IR* mRNA was expressed in mesenchymal condensations and in chondroblasts. These findings of the initial chondrogenesis of primary cartilage are comparable to the present findings of condylar cartilage, except for the *IGF-I* mRNA expression in the condylar anlage/perichondrium. Secondary cartilage is defined as cartilage derived from the periosteum, not from primary condensations.^[@R5]--[@R7]^ We previously demonstrated that the condylar cartilage is derived from ALP-positive, *type I collagen* mRNA-expressing periosteum-like cells continuous with the ossifying mandible.^[@R10]--[@R12],[@R15]^ Wang *et al.* also reported that *IGF-I* and *IGF-II* mRNA are expressed in osteoblasts in fetal long bone.^[@R34]^ Thus, *IGF-I* mRNA expression in the present study may reflect the nature of secondary cartilage derived from the periosteum.

Figure 5a, Schematic representations of expression patterns of *IGF-I*, -*II*, and -*IR* mRNA from E 13.0 to E16.0; appearance of *IGF-IR* under IGF-rich environment seemed to work as a trigger for subsequent condylar cartilage formation. B, Schematic representation of expression pattern of *IGFBP-2*, *-4*, and *-5* mRNA in the TMJ at E18.5; *IGFBP-5* mRNA is restrictedly expressed in the outer layer of perichondrium/fibrous cell zone; *IGFBP-4* mRNA is expressed in the perichondrium, anlagen of articular disc and lower joint cavity and continuous mesenchymal tissue; *IGFBP-2* mRNA is expressed in the anlagen of articular disc and lower joint cavity and in the fibrous mesenchymal tissue facing to the upper joint cavity, but not in the perichondrium; *IGFBP-2* seems to be involved in the formation of joint cavity.

Expression of *IGFBP* mRNA in developing condylar cartilage, articular disc, and joint cavities
-----------------------------------------------------------------------------------------------

In the present study, *IGFBP-5* mRNA was continuously detected in the outer layer of the periosteum/perichondrium/fibrous cell layer in the mandibular condyle, and *IGFBP-4* mRNA tended to be expressed mesenchymal tissues around the condylar cartilage (including the outer layer of the periosteum/perichondrium). This distribution pattern is similar to that of *IGF-I* and *IGF-II* mRNA, suggesting that *IGFBP-4* and *IGFBP-5* interact with these molecules. *IGFBP-4* and *IGFBP-5* immunostaining is detected in the upper layer of the condylar cartilage (chondroblasts, chondrocytes), especially in the anterior and posterior regions in growing rats^[@R35]^ and aged mice,^[@R23]^ indicating that the functions of these molecules are different from those in fetal mice observed in the present study. IGFBP-5 is complicated in terms of its function; it is reported to both inhibit and enhance IGF actions in bone, and IGF-independent mechanisms are also indicated.^[@R40]^ IGFBP-4 is considered to be a negative regulator of IGF action in a variety of cell types, but *IGFBP-4* gene knockout mice have a significantly reduced body size, and therefore the inhibitory action of IGFBP-4 must be evaluated in bone tissue in vivo. A possible explanation for this phenomenon is that IGFBP-4 binds IGFs, serving as a pericellular reservoir, and losses of the reservoir function in the knockout mice results in diminished local IGF-stimulated growth.^[@R40]^ Organ culture systems of developing condylar cartilage accompanied by antisense oligonucleotide or small interference RNA have been established^[@R19],[@R39]^ and may be useful for elucidating the complicated functions of these IGFBPs.

The present findings that *IGFBP* mRNA was expressed during formation of the articular disc and joint cavities are interesting. *IGFBP-4* mRNA was expressed in the anlage of the articular disc showing no sign of inferior joint cavity formation at E15.0, then continuously expressed in until identification of the anlage of the lower joint cavity at E16.0. When the upper joint cavity was formed at E18.5, *IGFBP-4* mRNA expression was still detected in the anlagen of the articular disc and lower joint cavity, but reduced in the fibrous mesenchymal tissue facing the upper joint cavity. Meanwhile, the enhanced expression of *IGFBP-2* mRNA was first recognized in the anlagen of the articular disc and lower joint cavity at E16.0 and continuously expressed in the anlagen of articular disc/lower joint cavity as well as in the fibrous mesenchymal tissue facing the upper joint cavity.

These expression patterns suggest the involvement of *IGFBP-2* and *IGFBP-4* in the formation of the TMJ, including the articular disc and joint cavities. In particular, *IGFBP-2* seems to be related to joint cavity formation, because no specific expression of *IGFBP-2* mRNA was detected in the angular cartilage at E18.5, which does not form joint structures. These findings are the first to suggest that the IGF system is involved in the formation of the TMJ and a schematic model of *IGFBP* expression at E18.5 is summarized in [Figure 5](#F5){ref-type="fig"}b.

Regarding TMJ formation and growth factors, Shibukawa *et al.* demonstrated failed formation of the articular disc and joint cavities fails in Indian hedgehog (IHH)-deficient mice, and suggested the involvement of IHH signaling in TMJ formation.^[@R14]^ Ikeda *et al.* investigated the development of synovial membrane cells on joint cavity surfaces.^[@R41]^ Furthermore, Matsuda *et al.* investigated cavity formation in terms of apoptosis, and concluded that apoptosis was not directly related.^[@R42]^ These phenomena are closely related to the regions expressing *IGFBPs* in the present study, suggesting that they may be regulated by the IGF system. Thus, analysis of the IGF system may be useful for further studies of TMJ formation.

In conclusion, the findings of the present study demonstrated mRNA expression for IGF molecules in the initial formation of the condylar cartilage, articular disc, and joint cavities.
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